Media stories about Exelixis (NASDAQ:EXEL) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Exelixis earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 89 out of 100, meaning that recent media coverage is very likely to have an effect on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

Exelixis (NASDAQ:EXEL) traded down 3.45% on Thursday, hitting $25.71. The stock had a trading volume of 5,701,655 shares. Exelixis has a 12 month low of $9.00 and a 12 month high of $28.45. The company has a market cap of $7.52 billion, a PE ratio of 642.75 and a beta of 1.89. The company has a 50-day moving average of $24.89 and a 200 day moving average of $21.88.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.02. Exelixis had a return on equity of 126.82% and a net margin of 1.37%. The business had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $85.27 million. During the same quarter in the previous year, the firm posted ($0.15) earnings per share. The company’s revenue was up 173.1% compared to the same quarter last year. On average, analysts predict that Exelixis will post $0.19 EPS for the current fiscal year.

Several research firms have recently commented on EXEL. Piper Jaffray Companies reaffirmed a “buy” rating and set a $29.00 price target on shares of Exelixis in a research report on Thursday. Cann reissued a “hold” rating on shares of Exelixis in a report on Wednesday, April 19th. Zacks Investment Research lowered shares of Exelixis from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 28th. Deutsche Bank AG lowered shares of Exelixis from a “buy” rating to a “hold” rating in a report on Thursday. Finally, SunTrust Banks, Inc. started coverage on shares of Exelixis in a report on Thursday, July 13th. They set a “buy” rating and a $33.00 price objective for the company. Five analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $24.07.

TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/03/somewhat-favorable-news-coverage-very-likely-to-impact-exelixis-exel-stock-price-updated-updated-updated.html.

In related news, insider Michael Morrissey sold 259,149 shares of the business’s stock in a transaction dated Friday, May 5th. The stock was sold at an average price of $22.24, for a total value of $5,763,473.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Patrick J. Haley sold 5,000 shares of the business’s stock in a transaction dated Tuesday, May 30th. The shares were sold at an average price of $18.46, for a total value of $92,300.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 619,737 shares of company stock worth $13,604,239. Insiders own 5.10% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Stock Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related stocks with our FREE daily email newsletter.